26_30,
Radiopharmaceutical positron Emission tomography (PET) is a popular radiopharmaceutical..to apply this PET radiopharmaceutical is under strict legislation for quality purpose..example 18F radiochemistry
Offen Fluroine -18 is used for radionuclide for diagnostic purpose it will be injected through IV..PET imaging F property provide advantage produced positron emission have longer half-life ..f contain less constraints on time and provide long images protocols to investigate and process of slower tracker kinetics upto 6hours..it needs purification and formulation also..The label peptide fluorination is a prosthetic group..f acetylation method is complex and time consuming..
There are half lives when using radioactive drugs..that is physical and biological half life it is important for radioactive from the pathway of radioactive decay, biological clearance..no half life important in effective half life..F-18 provide in the use of isotonic,sterile, pyrogenic free,clear, colour less citrate buffered solutions..this fluorine F_18 decays by positron emission has a half life of 109.7minutes..for diagnostic purpose 511 Kev gamma photons,results interaction of the emitted postron with an electron..The half life layer(HVL) for the 511KeV photons is 4.1mm lead (pb)..The interposition of different thicknesses of on will decrease the external radiation by 75%..
The extend of binding F18 to plasma proteins unknown..For healthy male person they receive with duration in 30sec..The arterial blood profile flurocine F18 reduced as a triexpotential decay curve..The effective half-life ranges in phase 0.2-0.3 min, 10-13min with mean and standard deviations (STD) of 11.6+1.1min, and 80-95min with a mean and STD of 88+4min..
ccoprssew treatment. 26-30) Give one example of a PET radiopharmaceutical that is obtained from a generator...
31-35) Briefly describe how you might design a radio pharmacy in a hospital environment so that it meets or exceeds current regulatory requirements, provides for the ALARA concept as well as minimizes radiation exposure to both patients and clinicians. 36-40) What is the "Blood Brain Barrier" and what does this mean for "diffusible" and "non-diffusible" radiopharmaceuticals for brain imaging? Give at least one example of a diffusible and non-diffusible radiopharmaceutical in your answer. Describe how you might design a new...